fda warning letters glp-1 compounders september 2025 news Issues Warnings Against Illegal Marketing FDA Issues 30 Warning Letters

The risk of ketotic hyperglycemia did not increase in the aforementioned meta-analysis (5861), and the DIAMOND-GLP-1 trial reported a decrease in the frequency of events ( In retrospective studies, acute pancreatitis was not reported in patients with T1D treated with GLP-1RA (67)

But improper handling at the user level negates that quality standard entirely

A standard treatment protocol requires a simple injection once a day

She says more scientific studies of the drugs are essential to better untangle how they work, and reveal all the different aspects of our health they impact, from inflammation and addiction to dementia